A Case Report: Antibody Response to 2-Dose Pfizer Vaccine and Johnson & A Case Report: Antibody Response to 2-Dose Pfizer Vaccine and Johnson &

Gita Taasoobshirazi*, Shiva Zaman and Katayun Taasoobshirazi

Recent research has shown that immunocompromised individuals are less likely to build detectible SARS-CoV-2 spike protein antibodies after vaccination. This is distressing for the 11.5 million individuals on some form of immunosuppressive therapy as the SARS-CoV-2 virus can lead to more severe illness and greater risk for death among these individuals. This study fills a gap in the research on COVID-19 vaccination in immunocompromised individuals with a case study of how a kidney transplant patient responded to a series of COVID-19 vaccines. The case study presented in this paper introduces the vaccination schedule and antibody testing of a kidney transplant patient in effort to assess the efficacy of a series of SARS-CoV-2 vaccines. The patient did not make SARS-CoV-2 spike protein antibodies, as assessed by a Spike Protein IgG Antibody blood test, after a two-dose schedule of the Pfizer vaccine. It was recommended that the patient receive a dose of the Johnson & Johnson vaccine. The patient then tested positive for SARS-CoV-2 spike protein antibodies. Recommendations are made, using the case study findings and current studies on COVID-19 vaccinations, for a possible approach to the vaccination of immunocompromised individuals and for future research on COVID-19 vaccination studies with immunosuppressed patients.

Published Date: 2021-10-15;